StoryFunding
Arrowhead sells its olpasiran royalties to Royalty Pharma for USD 250M upfront as Amgen readies Phase 3
Arrowhead, which discovered olpasiran and licensed it to Amgen in 2016, sold its future royalties on the drug to Royalty Pharma for USD 250M upfront plus up to USD 160M in milestones. Amgen said it would start enrolling a Phase 3 outcomes trial in December 2022.
- USD 250M upfront, up to USD 160M more tied to milestones.
- Arrowhead keeps up to USD 400M of milestone payments due from Amgen under the 2016 licence.
- In Phase 2, over 98% of patients on 75 mg or more saw Lp(a) fall by at least 95% versus placebo.